Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Enveric Biosciences Inc (ENVB) vs Lumen Technologies Inc (LUMN) Price & Performance

Enveric Biosciences IncTrade
Lumen Technologies IncTrade

Price performance (Past 24H)

Key statistics

Enveric Biosciences Inc vs Lumen Technologies Inc — how do they compare? Enveric Biosciences Inc trades at $1.56 (market cap $6.20M), while Lumen Technologies Inc trades at $6.38 (market cap $6.58B). The key difference: Lumen Technologies Inc is far larger — about 1061.3× Enveric Biosciences Inc's market cap, and Lumen Technologies Inc is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.

ENVBLUMN
Market Cap
$6.20M$6.58B
Sector
HealthMedia
52-Week High
$17.40$11.83
52-Week Low
$1.27$3.95
Enterprise Value
$1.30M$18.20B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Enveric Biosciences Inc

ENVB trades at $1.59, up 3.25% today, with a bullish technical signal driven by moving averages. The company, a biotechnology firm developing neuroplastogenic therapeutics, reported significant earnings beats in all quarters of 2025, including a positive EPS of $0.85 in Q4 versus an expected loss. Recent news highlights progress with its lead candidate EB-003, including non-hallucinogenic profile confirmations and FDA guidance alignment, though financials show negative ROE and ROA with net income of -$8.77M in 2025.

The outlook is cautiously optimistic due to strong analyst support (75% buy ratings) and clinical advancements, but high financial losses and reliance on financing cash flow pose risks. Stock performance hinges on successful drug development milestones and future profitability, with current sentiment buoyed by technical strength and positive pipeline updates.

Lumen Technologies Inc

LUMN stock trades at $6.375, down 3.99% today, amid a bearish technical signal and mixed earnings. The company reported a Q2 2026 loss of $0.07 per share, beating estimates, but revenue declined 9.3% year-over-year. Strategic revenues grew 14.1%, highlighting its digital transformation. CEO Kathleen Johnson purchased 100,000 shares on August 6, 2026, signaling insider confidence. Net cash flow was negative $886 million in 2025, though 2026 projections show improvement. The stock faces headwinds from high debt and legacy revenue declines.

LUMN offers a high-risk opportunity with a low P/S ratio of 0.54 and analyst consensus price target of $7.67, implying potential upside. However, persistent net losses, negative ROE of -78.94%, and $17.49 billion in long-term debt pose significant risks. Investors should weigh the digital growth potential against financial instability and cautious analyst sentiment, with 60.71% holding ratings.

Returns comparison

Trailing returns across standard periods

About Enveric Biosciences Inc

Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.

Read more on ENVB

About Lumen Technologies Inc

With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.

Read more on LUMN